Objective: To evaluate the effect of Qishen Yiqi pills on heart function and hypersensitive C-reactive protein in patients with chronic heart failure. Method: Totally 70 patients with chronic cardiac failure were randomly divided into the control group (35 cases) and the treatment group (35 cases) by the digital table method. Both groups received the standard chronic heart failure therapies

ie oral administration with Cefuroxime tablets (20 mg · d-1

qd)

Benaaepril Hydrochleride tablets (10 mg · d-1

qd) and Digaoxin tablets (for patients without contraindication

0.125 mg · d-1

qd). On the basis of the conventional therapies

the treatment group was additionally given Qishen Yiqi pills (0.5 g

tid). Both groups were treated for eight weeks. Their clinical efficacy

traditional Chinese medicine(TCM) syndrome score

left ventricular and systolic diameter(LVESD)

left ventricular and diastolic diameter(LVEDD)

left ventricular ejection fraction(LVEF)

b-type natriuretic peptide(BNP)

6-min walking test before and after the treatment were observed. Meanwhile

the content of hypersensitive C-reactive protein before and after the treatment was detected. Result: After the 8-week treatment

the treatment groups showed a better clinical efficacy and higher TCM syndrome score and total effective rate than the control group. Both groups showed statistical difference in heart color ultrasound

BNP

hypersensitive C-reactive protein and 6-min walking test (P<0.05). Conclusion: Qishen Yiqi pills can reduce the serum hypersensitive c-reactive protein level by inhibiting the expression of inflammatory factors

further improve heart function of patients with chronic cardiac failure and enhance the clinical efficacy.